Latest clinical evidence about the effect of PCSK9 monoclonal antibodies in patients with familial hypercholesterolaemia: an updated meta-analysis.
Sign Up to like & getrecommendations! Published in 2022 at "Endokrynologia Polska"
DOI: 10.5603/ep.a2021.0109
Abstract: INTRODUCTION Familial hypercholesterolaemia (FH) is the most common autosomal genetic disease of cholesterol metabolism disorder. Proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibody (mAb) is a new target lipid-regulating drug related to cholesterol metabolism that… read more here.
Keywords: familial hypercholesterolaemia; hypercholesterolaemia; effect pcsk9; patients familial ... See more keywords